Dimensional Fund Advisors Lp ownership in VM4 / Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

DE ˙ DB ˙ US9216591084

5,26 € ↑0,09 (1,74%)

2026-06-05
DEL PRIS

Security	DE:VM4 / Vanda Pharmaceuticals Inc.
Institution	Dimensional Fund Advisors Lp
Latest Disclosed Ownership	1,967,985 shares
Ownership	3.40%

2024-02-09 - Dimensional Fund Advisors Lp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,967,985 shares of Vanda Pharmaceuticals Inc. (DE:VM4). This represents 3.4 percent ownership of the company. In their previous filing dated 2023-02-10 , Dimensional Fund Advisors Lp had reported owning 2,853,832 shares, indicating a decrease of -31.04 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-02-09	2024-02-09	13G/A	2,853,832	1,967,985	-31.04	3.40	-32.00
2023-02-10	2023-02-10	13G		2,853,832		5.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-07	2026-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,771,593	-346,835	-16.37	12,240	-34.49	0.0025
2026-02-12	2025-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,118,428	-445,541	-17.38	18,682	46.03	0.0039
2025-11-12	2025-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,563,969	-21,788	-0.84	12,794	4.82	0.0027
2025-08-12	2025-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,585,757	46,082	1.81	12,205	4.70	0.0028
2025-05-13	2025-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,539,675	51,156	2.06	11,657	-2.20	0.0029
2025-02-13	2024-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,488,519	227,428	10.06	11,920	12.40	0.0029
2024-11-07	2024-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,261,091	247,284	12.28	10,604	-6.80	0.0026
2024-08-09	2024-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,013,807	292,172	16.97	11,379	60.82	0.0030
2024-05-10	2024-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,721,635	-246,350	-12.52	7,076	-14.81	0.0019
2024-02-07	2023-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,967,985	-196,573	-9.08	8,305	-11.19	0.0024
2023-11-09	2023-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,164,558	215,175	11.04	9,351	-27.21	0.0031
2023-08-09	2023-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,949,383	-834,307	-29.97	12,847	-32.03	0.0041
2023-05-12	2023-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,783,690	-70,142	-2.46	18,901	89,900.00	0.0064
2023-02-09	2022-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,853,832	118,856	4.35	21	-99.92	0.0062
2022-11-10	2022-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,734,976	54,951	2.05	27,021	-7.50	0.0104
2022-08-12	2022-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	2,680,025	416,866	18.42	29,212	14.12	0.0105
2022-05-13	2022-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,263,159	229,581	11.29	25,597	-19.78	0.0079
2022-02-09	2021-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	2,033,578	103,696	5.37	31,909	-3.53	0.0096
2021-11-12	2021-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,929,882	-36,545	-1.86	33,078	-21.79	0.0107
2021-08-12	2021-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,966,427	238,066	13.77	42,294	62.92	0.0134
2021-05-14	2021-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,728,361	176,123	11.35	25,960	27.27	0.0086
2021-03-08	2020-12-31	13F/A-2	VANDA PHARMACEUTICALS	COM	921659108	1,552,238	84,573	5.76	20,397	43.87	0.0074
2021-02-11	2020-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,552,238	84,573		20,397		7,366.3122
2020-11-12	2020-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,467,665	34,657	2.42	14,177	-13.52	0.0060
2020-08-13	2020-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,433,008	97,663	7.31	16,393	18.52	0.0072
2020-05-14	2020-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,335,345	137,624	11.49	13,831	-29.63	0.0072
2020-02-14	2019-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	1,197,721	76,805	6.85	19,655	32.04	0.0072
2019-11-12	2019-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	1,120,916	153,512	15.87	14,886	9.21	0.0058
2019-08-13	2019-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	967,404	182,786	23.30	13,631	-5.59	0.0053
2019-08-12	2019-03-31	13F/A-2	VANDA PHARMACEUTICALS	COM	921659108	784,618	253,913	47.84	14,438	4.12	0.0058
2019-05-10	2019-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	784,618	253,913		14,438
2019-02-26	2018-12-31	13F/A-1	VANDA PHARMACEUTICALS	COM	921659108	530,705	270,795	104.19	13,867	132.47	0.0063
2019-02-13	2018-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	530,705	270,795		13,867
2018-11-13	2018-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	259,910	259,910		5,965		0.0023
2016-11-10	2016-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	0	-25,128	-100.00	0	-100.00
2016-08-09	2016-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	25,128	0	0.00	281	33.81	0.0002
2016-05-13	2016-03-31	13F	VANDA PHARMACEUTICALS	COM	921659108	25,128	2,000	8.65	210	-2.33	0.0001
2016-02-10	2015-12-31	13F	VANDA PHARMACEUTICALS	COM	921659108	23,128	1,900	8.95	215	-10.04	0.0001
2015-11-13	2015-09-30	13F	VANDA PHARMACEUTICALS	COM	921659108	21,228	3,300	18.41	239	4.82	0.0002
2015-08-14	2015-06-30	13F	VANDA PHARMACEUTICALS	COM	921659108	17,928	17,928		228		0.0001

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.